Intended for healthcare professionals

Uses of isotretinoin in disorders other than acne

Haytham Al-Rawi and Philip J Hampton
Isotretinoin (13-cis-retinoic acid) is a vitamin A analogue that has been used for many years for the treatment of severe acne vulgaris. It was licensed in the UK in 1983 for the treatment of severe forms of acne (nodular, conglobate and scarring) only. More recently, it has been available in a topical formulation. However, over the years, dermatologists have used it with success in the treatment of a number of different skin conditions, including other acneiform conditions such as rosacea and hidradenitis suppurativa, as well as in disorders of keratinisation, the prevention of photoaging, and the prevention and treatment of skin cancers.
Dermatology in practice 2007; 15(4): 26–28
To continue reading this article, please sign in or register.

Dermatology in practice was previously supported by Wyeth from 2008 to 2010, by Wyeth and Serono in 2007, by Wyeth and Shire from 2005 to 2006, by Medlock Medical in 2004 and by SSL International from 2001 to 2003.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the publisher, Editor or Editorial Board. Accordingly the publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Dermatology in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2021 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 0262-5504 (Print) ISSN 2049-8446 (Online)